FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295836866> ?p ?o ?g. }

• W4295836866 endingPage "S1252" @default.
• W4295836866 startingPage "S1252" @default.
• W4295836866 abstract "SCLC is an aggressive neuroendocrine malignancy with poor prognosis. Development of new effective treatments was limited until the emergence of immune checkpoint inhibitors. The anti-PD-L1 therapies, atezolizumab and durvalumab, received EU approval for 1st-line (1L) treatment of extensive stage SCLC (ES-SCLC) in 2019 and 2020, respectively. To better characterise the emerging treatment landscape, we investigated SCLC treatment patterns in France, Germany, Spain, Italy and the UK. The study included all adults aged ≥18 years who were diagnosed with ES-SCLC and received any systemic treatments between Q1 2018 and Q4 2021 from a representative, retrospective oncology database. Baseline characteristics and treatment regimens by year, line of therapy, and platinum-sensitivity status were described. Of 5832 eligible patients (1L=4898, 2L=804, 3L+=130), 3843 were male (65.9%), with a median age of 66 years. Most patients were diagnosed with stage IV disease (88.4%). The most common 1L regimens over 2018–2021 were platinum + etoposide combination chemotherapies (91.8%, 86.0%, 62.9%, 42.3%, respectively; Table). Use of a platinum-based regimen + atezolizumab increased from 2019 to 2021 (5.6%, 27.3%, 40.0%, respectively). In 2021, platinum + atezolizumab was the most common 1L regimen in Germany (54.8%), France (46.2%) and the UK (43.7%). In France, platinum + durvalumab was the second most common therapy in 2021, accounting for 30.3% of 1L regimens, but this combination was uncommon in Germany (2.7%), Spain (2.0%), the UK (0.4%) and Italy (0.3%). Uptake of immune checkpoint inhibitor use was also observed in 2L treatment between 2019–2021 (3.8%, 4.9%, 11.0%, respectively), equally distributed for both platinum-resistant and platinum-sensitive patients.Table: 1543PRegimens by year in 1L ES-SCLC in EuropeRegimen2018 (n=1176)2019 (n=1190)2020 (n=1329)2021 (n=1203)Platinum1 + etoposide1079 (91.7)1023 (86.0)835 (62.8)509 (42.3)Platinum mono30 (2.6)49 (4.1)43 (3.2)49 (4.1)Platinum1 + atezolizumab067 (5.6)363 (27.3)481 (40.0)Platinum1 + durvalumab006 (0.5)53 (4.4)Anti-PD-(L)1/anti-CTLA-4 mono or combo22 (0.2)8 (0.7)32 (2.4)63 (5.2)Etoposide mono18 (1.5)11 (0.9)9 (0.7)8 (0.7)Other347 (4.0)32 (2.7)41 (3.1)40 (3.3)Data are n (%). 1Platinum-based chemo. 2Includes atezolizumab, durvalumab, nivolumab, pembrolizumab, tremelimumab, ipilimumab. 3Includes platinum combos, non-platinum-based chemo, and other non-chemo treatments Open table in a new tab Data are n (%). 1Platinum-based chemo. 2Includes atezolizumab, durvalumab, nivolumab, pembrolizumab, tremelimumab, ipilimumab. 3Includes platinum combos, non-platinum-based chemo, and other non-chemo treatments Since approval, use of anti-PD-L1 inhibitor combination therapy as a 1L treatment of ES-SCLC in Europe increased, although the speed of uptake varied between countries." @default.
• W4295836866 created "2022-09-15" @default.
• W4295836866 creator A5001823761 @default.
• W4295836866 creator A5007784517 @default.
• W4295836866 creator A5010899343 @default.
• W4295836866 creator A5011587741 @default.
• W4295836866 creator A5027183584 @default.
• W4295836866 creator A5042891316 @default.
• W4295836866 date "2022-09-01" @default.
• W4295836866 modified "2023-10-07" @default.
• W4295836866 title "1543P A retrospective cross-sectional study of treatment patterns in small cell lung cancer (SCLC) in Europe 2018–2021" @default.
• W4295836866 doi "https://doi.org/10.1016/j.annonc.2022.07.1637" @default.
• W4295836866 hasPublicationYear "2022" @default.
• W4295836866 type Work @default.
• W4295836866 citedByCount "0" @default.
• W4295836866 crossrefType "journal-article" @default.
• W4295836866 hasAuthorship W4295836866A5001823761 @default.
• W4295836866 hasAuthorship W4295836866A5007784517 @default.
• W4295836866 hasAuthorship W4295836866A5010899343 @default.
• W4295836866 hasAuthorship W4295836866A5011587741 @default.
• W4295836866 hasAuthorship W4295836866A5027183584 @default.
• W4295836866 hasAuthorship W4295836866A5042891316 @default.
• W4295836866 hasConcept C121608353 @default.
• W4295836866 hasConcept C126322002 @default.
• W4295836866 hasConcept C143998085 @default.
• W4295836866 hasConcept C2775949291 @default.
• W4295836866 hasConcept C2776694085 @default.
• W4295836866 hasConcept C2777701055 @default.
• W4295836866 hasConcept C2777742743 @default.
• W4295836866 hasConcept C2778119113 @default.
• W4295836866 hasConcept C2779399171 @default.
• W4295836866 hasConcept C2780030458 @default.
• W4295836866 hasConcept C2781413609 @default.
• W4295836866 hasConcept C71924100 @default.
• W4295836866 hasConceptScore W4295836866C121608353 @default.
• W4295836866 hasConceptScore W4295836866C126322002 @default.
• W4295836866 hasConceptScore W4295836866C143998085 @default.
• W4295836866 hasConceptScore W4295836866C2775949291 @default.
• W4295836866 hasConceptScore W4295836866C2776694085 @default.
• W4295836866 hasConceptScore W4295836866C2777701055 @default.
• W4295836866 hasConceptScore W4295836866C2777742743 @default.
• W4295836866 hasConceptScore W4295836866C2778119113 @default.
• W4295836866 hasConceptScore W4295836866C2779399171 @default.
• W4295836866 hasConceptScore W4295836866C2780030458 @default.
• W4295836866 hasConceptScore W4295836866C2781413609 @default.
• W4295836866 hasConceptScore W4295836866C71924100 @default.
• W4295836866 hasLocation W42958368661 @default.
• W4295836866 hasOpenAccess W4295836866 @default.
• W4295836866 hasPrimaryLocation W42958368661 @default.
• W4295836866 hasRelatedWork W2981320626 @default.
• W4295836866 hasRelatedWork W3115112240 @default.
• W4295836866 hasRelatedWork W3118442307 @default.
• W4295836866 hasRelatedWork W3134678141 @default.
• W4295836866 hasRelatedWork W3134820202 @default.
• W4295836866 hasRelatedWork W3154458198 @default.
• W4295836866 hasRelatedWork W3162554743 @default.
• W4295836866 hasRelatedWork W4212773896 @default.
• W4295836866 hasRelatedWork W4310923068 @default.
• W4295836866 hasRelatedWork W4319224783 @default.
• W4295836866 hasVolume "33" @default.
• W4295836866 isParatext "false" @default.
• W4295836866 isRetracted "false" @default.
• W4295836866 workType "article" @default.